Purpose/Objectives: To review the role of adjuvant therapy in the treatment of patients with colon cancer.
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C
olon cancer is the third most common cancer in men and women in the United States. The disease is one of the leading causes of cancer mortality and is responsible for about 200,000 deaths per year in Europe and the United States (Nicum, Midgley, & Kerr, 2003) . Although the cancer occurs frequently, the death rate has decreased since the mid-1980s, probably because of a combination of factors, including better screening and earlier detection and, more recently, improved treatments (Sargent & Murphy, 2003) . Chemotherapy options for patients diagnosed with advanced and metastatic disease have changed considerably. In addition to the approval of several new agents for metastatic colon cancer that have increased patient survival, effective new adjuvant therapy options have become available. The U.S. Food and Drug Administration (FDA) has approved new therapeutic approaches that are further improving survival in this population of patients.
Pathogenesis of Colon Cancer
A sequence of events has to occur for individuals to develop colon cancer; the disease generally develops over decades with multiple genetic occurrences (Williams et al., 2003) . Adenomas undergo changes that may cause development into carcinomas (Nicum et al., 2003) . Because the process can take many years, screening for colon cancer is of the utmost importance.
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Adenocarcinomas are malignant tumors of epithelial origin, stemming from the glandular epithelium of the colon mucosa. Adenocarcinomas infi ltrate the tissue, moving into muscularis mucosae, the submucosa, and, if not removed, the muscularis propria. The tumors may present as well, moderately, or poorly differentiated. About 15% of colon cancers occur in inherited patterns, including familial adenomatous polyposis (FAP) and hereditary nonpolyposis colon cancer. One of the initiating steps in colon carcinogenesis may be a mutation of the adenomatous polyposis coli tumor suppressor gene (the cause of FAP) (Williams et al.) . Further identifi cation of genes involved in the pathogenesis of colon cancer is under way.
Risk Factors for Colon Cancer
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